Online inquiry

IVTScrip™ mRNA-Human Androgen-binding protein, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK18475MR)

This product GTTS-WK18475MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the Androgen-binding protein protein. This product can be used in Sertoli cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001040.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 6462
UniProt ID P04278
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human Androgen-binding protein, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WK18475MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18892MR IVTScrip™ mRNA-Human AP4S1, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AP4S1
GTTS-WK2847MR IVTScrip™ mRNA-Human HAMP, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HAMP
GTTS-WK21934MR IVTScrip™ mRNA-Human APOL2, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APOL2
GTTS-WK14976MR IVTScrip™ mRNA-Human AP1M1, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AP1M1
GTTS-WK21284MR IVTScrip™ mRNA-Human AP2S1, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AP2S1
GTTS-WK15584MR IVTScrip™ mRNA-Human AP2S1, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AP2S1
GTTS-WK21185MR IVTScrip™ mRNA-Human ANK2, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANK2
GTTS-WK17275MR IVTScrip™ mRNA-Human Androgen-binding protein, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Androgen-binding protein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW